Mylan NV said Teva Pharmaceutical Industries Ltd. dismissed a patent infringement lawsuit against Mylan after a U.S. district court accepted Mylan's interpretation of the patents' claims.
Teva brought the lawsuit in the U.S. District Court for the District of Delaware alleging that Mylan's Glatiramer Acetate Injection 40 milligrams/milliliters infringed on two patents of its multiple sclerosis drug Copaxone 40 mg/ml.
The company added that Teva has agreed to withdraw the Irish equivalent to these patents from the proceeding filed in Ireland.
Mylan said Teva's only remaining patent challenges in the U.S. and Ireland against its generic relate to the three-times-a-week dosing regimen, which has already been invalidated at the U.K.'s High Court of Justice, at a U.S. district court and at the U.S. Patent Trial and Appeal Board. Teva is appealing the decisions in these cases.
